<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342664</url>
  </required_header>
  <id_info>
    <org_study_id>11899</org_study_id>
    <nct_id>NCT03342664</nct_id>
  </id_info>
  <brief_title>MIND: Artemis in the Removal of Intracerebral Hemorrhage</brief_title>
  <official_title>MIND: A Prospective, Multicenter Study of Artemis a Minimally Invasive Neuro Evacuation Device, in the Removal of Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this multicenter randomized controlled study is to compare the
      safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro
      Evacuation Device to best medical management for the treatment of intracerebral hemorrhage
      (ICH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to either minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management (MIS group) or best medical management alone (2:1) (MM).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>180 day mRS is blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Global disability (functional outcome) assessed via the ordinal modified Rankin score (mRS)</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via weighted modified Rankin Score (mRS)</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via modified Rankin Score (mRS)</measure>
    <time_frame>365 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed via Stroke Impact Scale</measure>
    <time_frame>180 and 365 days</time_frame>
    <description>Measures mobility and activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed via EQ-5D-5L</measure>
    <time_frame>180 and 365 days</time_frame>
    <description>Self assessment on activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Admission to hospital discharge (up to one year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU</measure>
    <time_frame># of days from admission (up to one year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of procedure</measure>
    <time_frame>Time in minutes at the time of surgery (up to one day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via modified Rankin Score (mRS) of ≤ 3</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via modified Rankin Score (mRS) of ≤ 2</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cerebral Hemorrhage</condition>
  <condition>Brain Hemorrhage</condition>
  <condition>Cerebral Parenchymal Hemorrhage</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Artemis + Medical Management (MIS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Medical Management Alone (MM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best medical management alone per standard of care at treating institution</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artemis + Medical Management</intervention_name>
    <description>Subject will receive best MM in addition to the MIS procedure with Artemis.</description>
    <arm_group_label>Artemis + Medical Management (MIS)</arm_group_label>
    <other_name>MIS + MM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Medical Management Alone (MM)</intervention_name>
    <description>Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.</description>
    <arm_group_label>Best Medical Management Alone (MM)</arm_group_label>
    <other_name>MM</other_name>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age ≥ 18 and ≤ 80

          2. Supratentorial ICH of volume ≥ 20 and ≤ 80 cc (measured using A x B X C/2 method)

          3. Hemostasis as confirmed by no arterial spot sign (may perform additional scan(s) every
             6 hours to demonstrate hemostasis)

          4. NIHSS ≥ 6

          5. GCS ≥ 5 and ≤ 15

          6. Historical mRS 0 or 1

          7. Symptom onset &lt; 24 hours prior to initial CT/MR

          8. MIS must be initiated within 72 hours of ictus/bleed

          9. SBP must be &lt; 180 mmHg and controlled at this level for at least 6 hours

        Exclusion Criteria:

          1. Imaging

               1. &quot;Arterial Spot Sign&quot; identified on final CTA indicating expanding hemorrhage

               2. Hemorrhagic lesion such as a vascular malformation (cavernous malformation, AVM
                  etc.), aneurysm, and/or neoplasm

               3. Hemorrhagic conversion of an underlying ischemic stroke

               4. Infratentorial hemorrhage

               5. Primary thalamic ICH (where the center of the hemorrhage emulates from the
                  thalamus)

               6. Associated intra-ventricular hemorrhage requiring treatment for IVH-related mass
                  effect or shift due to trapped ventricle (EVD for ICP management is allowed)

               7. Midbrain extension/involvement

               8. Absolute contraindication to CTA, conventional angiography and MRA

          2. Coagulation Issues

               1. Absolute requirement for long-term anti-coagulation (e.g., mechanical valve
                  replacement (bio-prostatic valve is permitted), high risk atrial fibrillation)

               2. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency

               3. Platelet count &lt; 100 x 10^3 cells/mm3 or known platelet dysfunction

               4. INR &gt; 1.4, elevated prothrombin time or activated partial thromboplastin time
                  (aPTT), which cannot be corrected or otherwise accounted for (i.e., lupus
                  anti-coagulant)

               5. Use of direct factor Xa inhibitors (e.g. apixaban, rivaroxaban, fondaparinux)
                  within last 48 hours

          3. Patient Factors

               1. Traumatic ICH

               2. High risk atrial fibrillation (e.g., mitral stenosis with atrial fibrillation)
                  and/or symptomatic carotid stenosis

               3. Requirement for emergent surgical decompression or uncontrolled ICP after EVD

               4. Unable to obtain consent per Institution Review Board/Ethics Committee policy

               5. Pregnancy or positive pregnancy test (either serum or urine). Women of
                  child-bearing potential must have a negative pregnancy test prior to enrollment

               6. Severe active infection requiring treatment (e.g. sepsis or purulent wound) at
                  the time of enrollment

               7. Renal failure indicated by creatinine &gt; 2 mg/dL or undergoing dialysis

               8. Any comorbid disease or condition expected to compromise survival or ability to
                  complete follow-up assessments through 365 days

               9. Based on investigator's judgement, patient is unwilling or unable to comply with
                  protocol follow up appointment schedule

              10. Active drug or alcohol use or dependence that, in the opinion of the site
                  investigator would interfere with adherence to study requirements

              11. Currently participating in another interventional (drug, device, etc) clinical
                  trial. Patients in observational, natural history, and/or epidemiological studies
                  not involving intervention are eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marisol Clemens</last_name>
    <phone>+1 510 995 2494</phone>
    <email>mclemens@penumbrainc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke Lawson</last_name>
    <phone>+1 510 995 2183</phone>
    <email>blawson@penumbrainc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Ullman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Matouk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Washington</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Sigounas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Babak Jahromi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Fraser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert James, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Washington, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Neuroscience Institute</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Saphier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Ullman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Kellner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Fiorella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Schirmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUSC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Andrews, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Nickele, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Ryan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Levitt, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICH</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebral Hemorrhage</keyword>
  <keyword>Intracranial Hemorrhage</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain bleed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

